NASDAQ:KDMN - Kadmon Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.25
  • Forecasted Upside: 28.87 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.73
▼ -0.09 (-1.02%)

This chart shows the closing price for KDMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kadmon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDMN

Analyst Price Target is $11.25
▲ +28.87% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Kadmon in the last 3 months. The average price target is $11.25, with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 28.87% upside from the last price of $8.73.

This chart shows the closing price for KDMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Kadmon. This rating has held steady since June 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021MizuhoDowngradeBuy ➝ Neutral$9.50Medium
9/10/2021UBS GroupDowngradeBuy ➝ Neutral$9.50Low
9/9/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $9.50Low
9/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformLow
8/9/2021HC WainwrightReiterated RatingBuy$20.00Medium
7/19/2021Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$9.00 ➝ $10.00Low
7/19/2021OppenheimerBoost Price TargetOutperform$8.00 ➝ $9.00High
5/20/2021UBS GroupInitiated CoverageBuy$9.00High
3/26/2021HC WainwrightReiterated RatingBuy$20.00High
3/5/2021Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00High
2/10/2021HC WainwrightReiterated RatingBuy$25.00Low
11/11/2020MizuhoInitiated CoverageBuy$13.00Medium
11/10/2020MizuhoInitiated CoverageBuy$13.00High
11/9/2020HC WainwrightReiterated RatingBuy$25.00High
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
10/1/2020Raymond JamesReiterated RatingBuyMedium
9/22/2020OppenheimerReiterated RatingBuy$8.00High
8/7/2020Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00High
6/28/2020HC WainwrightReiterated RatingBuy$25.00Low
5/22/2020HC WainwrightReiterated RatingBuy$25.00Low
5/19/2020Raymond JamesInitiated CoverageOutperform$7.00High
5/7/2020OppenheimerReiterated RatingBuy$8.00Medium
3/5/2020OppenheimerReiterated RatingBuy$8.00High
2/26/2020HC WainwrightReiterated RatingBuy$25.00Low
1/10/2020Nomura SecuritiesInitiated CoverageBuy$10.00High
11/12/2019Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $10.00High
9/5/2019Cantor FitzgeraldInitiated CoverageOverweight$8.00Low
6/26/2019OppenheimerInitiated CoverageOutperform$6.00High
3/12/2019HC WainwrightReiterated RatingBuy$25.00High
2/26/2019CitigroupUpgradeNeutral ➝ Buy$2.77Low
11/12/2018HC WainwrightReiterated RatingBuy$25.00High
10/17/2018WBB SecuritiesUpgradeSell ➝ Hold$2.90Medium
8/13/2018HC WainwrightSet Price TargetBuy$25.00Medium
3/9/2018HC WainwrightReiterated RatingBuy$25.00High
2/13/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$7.00 ➝ $9.00High
2/13/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$16.00High
12/15/2017HC WainwrightReiterated RatingBuy$25.00Low
11/17/2017HC WainwrightReiterated RatingBuy$25.00N/A
10/9/2017WBB SecuritiesDowngradeHold ➝ Sell$3.00N/A
8/2/2017Piper Jaffray CompaniesSet Price TargetBuy$7.00Medium
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$7.00Medium
6/26/2017HC WainwrightReiterated RatingBuy$25.00High
3/27/2017CitigroupLower Price TargetNeutral$6.00 ➝ $4.00High
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$36.10 ➝ $23.00Low
3/16/2017WBB SecuritiesUpgradeSell ➝ Hold$3.25Medium
3/14/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$7.00High
2/1/2017HC WainwrightReiterated RatingBuy$25.00N/A
11/21/2016JMP SecuritiesReiterated RatingBuyN/A
11/10/2016Jefferies Financial GroupReiterated RatingBuy$12.00 ➝ $10.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 7 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
8/20/2021
  • 11 very positive mentions
  • 31 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
9/19/2021

Current Sentiment

  • 11 very positive mentions
  • 31 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Kadmon logo
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
Read More

Today's Range

Now: $8.73
Low: $8.73
High: $8.86

50 Day Range

MA: $5.34
Low: $3.55
High: $9.09

52 Week Range

Now: $8.73
Low: $3.14
High: $9.20

Volume

9,532,102 shs

Average Volume

4,703,043 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Kadmon?

The following Wall Street sell-side analysts have issued research reports on Kadmon in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Oppenheimer Holdings Inc., Raymond James, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for KDMN.

What is the current price target for Kadmon?

6 Wall Street analysts have set twelve-month price targets for Kadmon in the last year. Their average twelve-month price target is $11.25, suggesting a possible upside of 28.9%. HC Wainwright has the highest price target set, predicting KDMN will reach $20.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $9.00 for Kadmon in the next year.
View the latest price targets for KDMN.

What is the current consensus analyst rating for Kadmon?

Kadmon currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KDMN, but not buy more shares or sell existing shares.
View the latest ratings for KDMN.

What other companies compete with Kadmon?

How do I contact Kadmon's investor relations team?

Kadmon's physical mailing address is 450 East 29th Street, New York NY, 10016. The company's listed phone number is (833) 900-5366 and its investor relations email address is [email protected] The official website for Kadmon is www.kadmon.com.